Sort
39,280 grants matching “leukemia”
The reduction of NLRX1 and its role in pulmonary aging
$343,375Min-Jong Kang · Yale University · R01 · FY2018 · AG
The reduction of NLRX1 and its role in pulmonary aging
$343,375Min-Jong Kang · Yale University · R01 · FY2020 · AG
Pax5:Hematopoietic Transcription Factor Involved in ALL
$343,368Harold H Koeffler · Cedars-Sinai Medical Center · R01 · FY2013 · CA
INFLAMMATORY MONOCYTES IN ALLO-HSCT
$343,365Eric G Pamer · Sloan-Kettering Inst Can Research · P01 · FY2009 · CA
Retroviral Subversion of ERAD and Intrinsic Immunity
$343,330Jaquelin Page Dudley · University Of Texas At Austin · R01 · FY2013 · CA
Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia
$343,259Sinisa Dovat · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2019 · CA
The roles of SOCS5 in T-ALL migration and tissue infiltration
$343,258Ksenia Matlawska-Wasowska · University Of New Mexico Health Scis Ctr · R01 · FY2020 · CA
The roles of SOCS5 in T-ALL migration and tissue infiltration
$343,258Ksenia Matlawska-Wasowska · University Of New Mexico Health Scis Ctr · R01 · FY2019 · CA
HIV-1 AND HIV-2 INFECTION OF NON-DIVIDING CELLS
$343,237University Of Pennsylvania · R01 · FY2001 · AI
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
$343,222Jianjun Chen · University Of Chicago · R01 · FY2014 · CA
Mechanism of Pancreatic Carcinogenesis
$343,220Martin Ernesto Fernandez-Zapico · Mayo Clinic Rochester · R01 · FY2018 · CA
Development of ESP: Structural &Functional Oncogenomics
$343,210University Of California San Francisco · R33 · FY2005 · CA
Increasing the Selectivity of Hybrid Mass Spectrometry using Multidimensional Ion Mobility Spectrometry
$343,173Matthew Francis Bush · University Of Washington · R01 · FY2020 · GM
Understanding how ZFHX4 drives the glioblastoma tumor propagating cell state
$343,164Milan Girish Chheda · Washington University · R01 · FY2019 · NS
Molecular understanding of cytokine-Ras signals in leukemic bone marrow
$343,163Jeroen Roose · University Of California, San Francisco · R01 · FY2019 · CA
Characterization of ERK8, a new MAPK in Lung
$343,125University Of Chicago · R01 · FY2005 · HL
NANOTECH BIOMARKERS FOR RENAL CANCER INTERVENTION: CLINICAL VALIDATION & UTILITY
$343,125Jeremiah J Morrissey · Washington University · R01 · FY2016 · CA
NANOTECH BIOMARKERS FOR RENAL CANCER INTERVENTION: CLINICAL VALIDATION & UTILITY
$343,125Jeremiah J Morrissey · Washington University · R01 · FY2018 · CA
The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis
$343,125Olga A Guryanova · University Of Florida · R01 · FY2023 · DK
NANOTECH BIOMARKERS FOR RENAL CANCER INTERVENTION: CLINICAL VALIDATION & UTILITY
$343,125Jeremiah J Morrissey · Washington University · R01 · FY2017 · CA
The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis
$343,125Olga A Guryanova · University Of Florida · R01 · FY2019 · DK
The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis
$343,125Olga A Guryanova · University Of Florida · R01 · FY2020 · DK
Biology of Imatinib-Resistant Mutants of BCR-ABL
$343,125Oregon Health And Science University · R01 · FY2005 · HL
The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis
$343,125Olga A Guryanova · University Of Florida · R01 · FY2022 · DK
Characterization of ERK8, a new MAPK in Lung
$343,125University Of Chicago · R01 · FY2004 · HL